• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

走向负向:基因组学在优化医疗处方中的应用。

Going to the negative: genomics for optimized medical prescription.

机构信息

Georgia Institute of Technology, School of Biological Sciences, Krone EBB, Atlanta, USA.

出版信息

Nat Rev Genet. 2019 Jan;20(1):1-2. doi: 10.1038/s41576-018-0061-7.

DOI:10.1038/s41576-018-0061-7
PMID:30348998
Abstract

Personalized medicine promises to advance and improve health by targeting the right medication to the right person at the right time, thus maximizing the proportion of treated patients who achieve an effective response to therapy. This Comment article makes the complementary argument that equally important benefits will derive from negative prediction, namely by identifying those individuals who are either not actually in need of, or unlikely to respond to, a drug. Reduction of unnecessary prescription could conceivably save health-care systems many billions of dollars with very little detrimental impact on outcomes.

摘要

个性化医疗有望通过在恰当的时间为恰当的患者提供恰当的药物来提升和改善健康,从而使治疗有反应的患者比例最大化。本文提出了一个互补的观点,即阴性预测同样重要,它可以识别出那些实际上不需要药物或不太可能对药物有反应的个体。减少不必要的处方用药可能会为医疗保健系统节省数十亿美元,而对结果几乎没有不利影响。

相似文献

1
Going to the negative: genomics for optimized medical prescription.走向负向:基因组学在优化医疗处方中的应用。
Nat Rev Genet. 2019 Jan;20(1):1-2. doi: 10.1038/s41576-018-0061-7.
2
Omics and drug response.组学与药物反应。
Annu Rev Pharmacol Toxicol. 2013;53:475-502. doi: 10.1146/annurev-pharmtox-010510-100502. Epub 2012 Nov 5.
3
Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.机构简介:佛罗里达大学和 Shands 医院个性化医学计划:药物遗传学的临床实施。
Pharmacogenomics. 2013 May;14(7):723-6. doi: 10.2217/pgs.13.59.
4
Genomics, personalized medicine, and supportive cancer care.基因组学、个性化医疗与癌症支持性护理。
Am Soc Clin Oncol Educ Book. 2015:9-16. doi: 10.14694/EdBook_AM.2015.35.9.
5
Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions.药物基因组学在个性化精准医学中的临床应用:障碍与解决方案
J Pharm Sci. 2017 Sep;106(9):2368-2379. doi: 10.1016/j.xphs.2017.04.051. Epub 2017 Jun 13.
6
The opportunities and challenges of implementing genomics-informed personalized medicine.实施基于基因组学的个性化医疗所面临的机遇与挑战。
Clin Pharmacol Ther. 2013 Aug;94(2):181-2. doi: 10.1038/clpt.2013.71.
7
Personalized medicine: potential, barriers and contemporary issues.个性化医学:潜力、障碍和当代问题。
Curr Drug Metab. 2012 Sep 1;13(7):1000-6. doi: 10.2174/138920012802138615.
8
Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array.实施个性化医学:开发一种具有成本效益的定制型药物基因组学分型基因芯片。
Clin Pharmacol Ther. 2012 Oct;92(4):437-9. doi: 10.1038/clpt.2012.125. Epub 2012 Aug 22.
9
From systems biology and functional genomics to personalized health. 5th Biologie Prospective Santorini Conference, Island of Santorini, Greece, September 30-October 2, 2010.从系统生物学和功能基因组学到个性化健康。第五届圣托里尼前瞻性生物学会议,希腊圣托里尼岛,2010年9月30日至10月2日。
Drug Metabol Drug Interact. 2011;26(1):41-2. doi: 10.1515/DMDI.2011.104. Epub 2011 Mar 16.
10
Genomic Medicine in Primary Care.基层医疗中的基因组医学。
S D Med. 2017;Spec No:62-65.

引用本文的文献

1
Establishment, maintenance and application effect analysis of the prescription pre-review system in a tertiary hospital in China.中国某三级医院处方前置审核系统的建立、维护及应用效果分析
BMC Health Serv Res. 2025 Jul 1;25(1):853. doi: 10.1186/s12913-025-12901-8.
2
Misinterpretation and misapplication of biomarkers in inflammatory bowel disease: how do we avoid this?炎症性肠病中生物标志物的错误解读与误用:我们如何避免?
Expert Rev Gastroenterol Hepatol. 2025 Apr;19(4):359-363. doi: 10.1080/17474124.2025.2482980. Epub 2025 Mar 25.
3
Dual exposure-by-polygenic score interactions highlight disparities across social groups in the proportion needed to benefit.
通过多基因评分的双重暴露相互作用凸显了不同社会群体在受益所需比例方面的差异。
medRxiv. 2024 Jul 30:2024.07.29.24311065. doi: 10.1101/2024.07.29.24311065.
4
Ayurgenomics-based frameworks in precision and integrative medicine: Translational opportunities.精准与整合医学中基于阿育吠陀基因组学的框架:转化机遇。
Camb Prism Precis Med. 2023 Jun 15;1:e29. doi: 10.1017/pcm.2023.15. eCollection 2023.
5
New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer.三阴性乳腺癌的新生物标志物与治疗进展
Diagnostics (Basel). 2023 Jun 2;13(11):1949. doi: 10.3390/diagnostics13111949.
6
Polygenic Contributions to Chronic Overlapping Pain Conditions in a Large Electronic Health Record Sample.多基因对大型电子健康记录样本中慢性重叠性疼痛状况的贡献。
J Pain. 2023 Jun;24(6):1056-1068. doi: 10.1016/j.jpain.2023.01.018. Epub 2023 Feb 3.
7
Improved genetic prediction of complex traits from individual-level data or summary statistics.从个体水平数据或汇总统计信息中提高复杂性状的遗传预测能力。
Nat Commun. 2021 Jul 7;12(1):4192. doi: 10.1038/s41467-021-24485-y.
8
Highly elevated polygenic risk scores are better predictors of myocardial infarction risk early in life than later.高得多的多基因风险评分在生命早期预测心肌梗死风险比后期更好。
Genome Med. 2021 Jan 28;13(1):13. doi: 10.1186/s13073-021-00828-8.
9
Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues.多基因风险评分在临床中的应用:熟悉的伦理问题需要新的视角。
Genome Med. 2021 Jan 28;13(1):14. doi: 10.1186/s13073-021-00829-7.
10
Polygenic risk scores: from research tools to clinical instruments.多基因风险评分:从研究工具到临床工具。
Genome Med. 2020 May 18;12(1):44. doi: 10.1186/s13073-020-00742-5.